Table of contents
- Trial overview
- Who is being studied
- Study phases and designs
- What the trials measure
- Trial products and comparators
- Key patient terms
Trial overview
The source data includes three authorised interventional trials that mention Xylitol as part of the study treatment. One trial is in Phase 4 for people with congestive heart failure, and two trials are in kidney disease, including Phase 2 and Phase 3 studies in end-stage kidney disease.[1][2][3]
These studies are not general drug information studies; they are clinical research projects that test specific dialysis-related treatments and outcomes in defined patient groups.[1][2][3]
Who is being studied
Two trials focus on end-stage kidney disease, which means very advanced kidney failure.[2][3] These studies are aimed at people starting or receiving peritoneal dialysis, which is a kidney treatment that uses the lining of the belly to help remove waste and extra fluid.[2][3]
One trial focuses on congestive heart failure and looks at whether peritoneal ultrafiltration can help prevent worsening of the condition.[1] In simple terms, the study is asking whether the treatment can help patients avoid hospital stays, fluid problems, and kidney decline.[1]
Study phases and designs
The heart failure study is a Phase 4 interventional trial with 84 planned participants.[1] Phase 4 studies usually look at how a treatment performs in a more real-world setting after earlier testing.[1]
The kidney disease safety study is a Phase 2 pilot trial with 28 planned participants.[2] A pilot study is a small early study that helps researchers check whether a treatment appears safe and workable before larger research is done.[2]
The kidney disease comparison study is a Phase 3 trial with 175 planned participants.[3] This phase is used to compare a new treatment with standard care and see whether it performs at least as well as the current treatment.[3]
What the trials measure
The Phase 4 heart failure study uses a composite endpoint, which means it combines several important results into one main outcome.[1] The outcomes include patient death, hospitalisation for cardiovascular causes, the need for stronger diuretics or hemofiltration, a rise of at least 30% in loop diuretic dose, and worsening kidney function defined by very low eGFR.[1]
The Phase 2 kidney study mainly focuses on safety, with repeated checks for adverse events, physical examination findings, vital signs, blood chemistry, blood counts, 24-hour urine output, 24-hour dialysate analysis, weekly Kt/V urea, and residual kidney function.[2] These measures help researchers see whether the treatment is tolerated and whether kidney dialysis is working as expected.[2]
The Phase 3 kidney study measures weekly Kt/V urea at several visits.[3] This is a dialysis effectiveness measure that shows how well waste is being removed from the body.[3]
Trial products and comparators
In the heart failure study, the intervention is listed as PolyCore used intraperitoneally, meaning it is placed into the abdominal cavity for treatment.[1] The study summary says the goal is to see whether peritoneal ultrafiltration with PolyCore affects the main combined outcome of death or worsening condition.[1]
In the Phase 2 kidney study, PolyCore is described as a ternary combination of Xylitol, L-Carnitine, and Polydextrin.[2] The study summary says the main objective is to evaluate safety through ongoing monitoring of adverse events and clinical tests.[2]
In the Phase 3 kidney study, Xylocore is described as a glucose-sparing experimental solution for peritoneal dialysis.[3] The trial compares Xylocore with many standard glucose-based dialysis solutions and aims to show non-inferiority, which means it is not worse than the standard treatment for the main measure.[3]
The source data lists several comparator products in the Phase 3 trial, including bicaVera, PHYSIONEAL, FIXIONEAL, balance, Dianeal PDG4, and equiBalance, all used intraperitoneally.[3] This shows that the study is testing Xylitol-containing treatment against common dialysis solutions used in practice.[3]
Key patient terms
Interventional trial means the researchers give a treatment and watch what happens, instead of only observing usual care.[1][2][3]
Residual kidney function means the kidney still has some working ability, even if it is reduced.[2]
Adverse events are unwanted health problems that happen during a study, and they are tracked closely for safety.[2]
eGFR is a blood-test-based estimate of kidney filtering ability, and very low values can show serious kidney decline.[1]
Hemofiltration is a blood-cleaning treatment used in severe illness when the body needs extra help removing fluid and waste.[1]
